XINTELA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3 SEK | +0.67% |
|
+1.35% | +10.70% |
| 05-24 | Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-23 | Xintela and EQGen Biomedical to Collaborate to Develop EQSTEM Stem Cell Treatment for Horses | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| XINTELA AB | Other Biotechnology & Medical Research | +0.67% | +1.35% | +10.70% | +11.52% | -94.60% | 16.05M | - | - | - |
Technical Rankings Surperformance
- Stock Market
- Equities
- XINT Stock
- Charts Xintela AB
- Comparison Chart
